Hormonal maintenance therapy can increase chances of survival in women with rare ovarian, says new study

By  ,  Onlymyhealth editorial team
Feb 22, 2017

Good news for women with a rare type of epithelial ovarian or peritoneum cancer as a new study reveals that, hormonal maintenance therapy (HMT) may drastically improve survival in women having low-grade serous carcinoma (LGSC). This research was published in the Journal of Clinical Oncology.



According to the researchers, LGSC accounts for 10 percent of serous carcinomas of the ovary/peritoneum. It is diagnosed in women, who are in their early 40s and 50s. However, teenagers and women in their 20s and 30s also may develop the condition. The findings of this study could one day represent a major improvement to frontline standard of care.

There is a true unmet need for these patients -- roughly, 70 percent of women with this disease will experience a recurrence of the cancer at some point. Another research conducted by David M. Gershenson, M.D., professor, Gynecologic Oncology and Reproductive Medicine, in 2004 also demonstrated that hormonal therapy showed promise in the recurrent setting, with most patients responding or having stable disease, suggest the researchers.

The study analyzed data from 203 women with stage II-IV LGSC and were getting treatment between 1981 and 2013 to evaluate the effect of HMT, compared with surveillance, after surgery and chemotherapy.

Women who received HMT (70 patients) showed an average progression-free survival (PFS) of 64.9 months compared with 26.4 months for those in the surveillance group (133 patients). Overall survival (OS) was 115.7 months following HMT, versus 102.7 months for the surveillance group.

Hormonal therapy has shown promising results in reducing cancer recurrence, and there is increasing interest in integrating this approach into first-line therapy. If confirmatory research in a clinical trial setting shows hormonal maintenance therapy can prevent or delay recurrence of this cancer subtype, it would be practice changing," said Gershenson.

Though recruitment for this patient population is challenging given the rarity of the disease, Gershenson noted that a prospective international Phase three clinical trial has been designed.


Image source : Getty


Health news source : ANI

Is it Helpful Article?YES539 Views 0 Comment
I have read the Privacy Policy and the Terms and Conditions. I provide my consent for my data to be processed for the purposes as described and receive communications for service related information.
This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK